These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33050360)

  • 41. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
    Achutha AS; Pushpa VL; Suchitra S
    J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
    Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
    Molecules; 2020 May; 25(10):. PubMed ID: 32408547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
    Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
    Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biflavonoids from
    Lokhande K; Nawani N; K Venkateswara S; Pawar S
    J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Putative SARS-CoV-2 M
    Mazzini S; Musso L; Dallavalle S; Artali R
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
    Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
    J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
    Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
    J Chem Theory Comput; 2020 Nov; 16(11):7160-7172. PubMed ID: 33090785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
    Shah B; Modi P; Sagar SR
    Life Sci; 2020 Jul; 252():117652. PubMed ID: 32278693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laser irradiated phenothiazines: New potential treatment for COVID-19 explored by molecular docking.
    Udrea AM; Avram S; Nistorescu S; Pascu ML; Romanitan MO
    J Photochem Photobiol B; 2020 Oct; 211():111997. PubMed ID: 32829256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
    Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
    Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
    Sies H; Parnham MJ
    Free Radic Biol Med; 2020 Aug; 156():107-112. PubMed ID: 32598985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MS
    Zhang ZJ; Wu WY; Hou JJ; Zhang LL; Li FF; Gao L; Wu XD; Shi JY; Zhang R; Long HL; Lei M; Wu WY; Guo DA; Chen KX; Hofmann LA; Ci ZH
    J Integr Med; 2020 May; 18(3):229-241. PubMed ID: 32307268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design.
    Bzówka M; Mitusińska K; Raczyńska A; Samol A; Tuszyński JA; Góra A
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32353978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.